Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Al Malki, Monzr M  [Clear All Filters]
2024
Nakamura R, La Rosa C, Yang D, Hill JA, Rashidi A, Choe H, Zhou Q, Lingaraju CRaj, Kaltcheva T, Longmate J, et al. A phase II randomized, placebo-controlled, multicenter trial to evaluate the efficacy of cytomegalovirus PepVax vaccine in preventing cytomegalovirus reactivation and disease after allogeneic hematopoietic stem cell transplant. Haematologica. 2024.
2023
Braun A, Liu L, Malki MMAl, Becker PS. Haploidentical hematopoietic cell transplant recipient presents with late-onset Epstein Barr virus-associated posttransplant lymphoproliferative disorder. EJHaem. 2023;4(3):848-851.
Ngo D, Chen J, Tinajero J, Aribi A, Arslan S, Marcucci G, Nakamura R, Malki MMAl, Forman SJ, Dadwal S, et al. The impact of SARS-CoV2 vaccines on the incidence of graft versus host disease in allogeneic hematopoietic stem cell transplant recipients: a single-center retrospective study. Stem Cell Res Ther. 2023;14(1):95.
Sallman DA, Malki MMAl, Asch AS, Wang ES, Jurcic JG, Bradley TJ, Flinn IW, Pollyea DA, Kambhampati S, Tanaka TN, et al. Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study. J Clin Oncol. 2023:JCO2201794.
Bolaños-Meade J, Hamadani M, Wu J, Malki MMAl, Martens MJ, Runaas L, Elmariah H, Rezvani AR, Gooptu M, Larkin KT, et al. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. N Engl J Med. 2023;388(25):2338-2348.
Mei M, Palmer J, Tsai NNi-Chun, Simpson J, O'Hearn J, Stein A, Forman S, Spielberger R, Cai J-L, Htut M, et al. Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma. Clin Lymphoma Myeloma Leuk. 2023.
Elmariah H, Otoukesh S, Kumar A, Ali H, Arslan S, Shouse G, Pourhassan H, Nishihori T, Faramand R, Mishra A, et al. Sirolimus is an acceptable alternative to tacrolimus for graft-versus-host disease prophylaxis after haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide. Transplant Cell Ther. 2023.
Peton B, Taniguchi M, Mangiola M, Malki MMAl, Gendzekhadze K. Specificity of HLA monoclonal antibodies and their use to determine HLA expression on lymphocytes and peripheral blood stem cells. HLA. 2023.
2022
Pourhassan H, La Rosa C, Chiuppesi F, Puing A, Aldoss I, Park Y, Zhou Q, Karpinski V, Faircloth K, Kaltcheva T, et al. Successful outcome of pre-engraftment COVID-19 in an HCT patient: impact of targeted therapies and cellular immunity. Blood Adv. 2022.
2021
Ciurea SO, Malki MMAl, Kongtim P, Zou J, Aung FM, Rondon G, Chen J, Taniguchi M, Otoukesh S, Nademanee A, et al. Treatment of Allosensitized Patients Receiving Allogeneic Transplantation. Blood Adv. 2021.
2020
Aldoss I, La Rosa C, Baden LR, Longmate J, Ariza-Heredia EJ, Rida WN, Lingaraju CRaj, Zhou Q, Martinez J, Kaltcheva T, et al. Poxvirus Vectored Cytomegalovirus Vaccine to Prevent Cytomegalovirus Viremia in Transplant Recipients: A Phase 2, Randomized Clinical Trial. Ann Intern Med. 2020.
2019
Malki MMAl, Gendzekhadze K, Yang D, Mokhtari S, Parker P, Karanes C, Palmer J, Snyder D, Forman SJ, Nademanee A, et al. Long-term outcome of allogeneic hematopoietic stem cell transplantation from unrelated donor using tacrolimus/sirolimus-based GVHD prophylaxis: impact of HLA mismatch. Transplantation. 2019.
Mei M, Gupta R, O'Donnell M, Malki MMAl, Aldoss I, Ali H, Farol L, Snyder D, Forman SJ, Nakamura R, et al. Post-allogeneic eculizumab as prophylaxis against hemolysis and thrombosis for patients with hematologic disorders associated with PNH clones. Biol Blood Marrow Transplant. 2019.
Yuan S, Yang D, Nakamura R, Zhuang L, Malki MMAl, Wang S. RBC and platelet transfusion support in the first 30 and 100 days after haploidentical hematopoietic stem cell transplantation. Transfusion. 2019.
2016
Al-Homsi A-S, Feng Y, Duffner U, Malki MMAl, Goodyke A, Cole K, Muilenburg M, Abdel-Mageed A. Bortezomib for the Prevention and Treatment of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. Exp Hematol. 2016.